Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
Crossref DOI link: https://doi.org/10.1007/s12094-017-1684-4
Published Online: 2017-06-02
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lopez-Vivanco, G.
Salvador, J.
Diez, R.
López, D.
De Salas-Cansado, M.
Navarro, B. http://orcid.org/0000-0001-5738-6790
De la Haba-Rodríguez, J.
Funding for this research was provided by:
Roche Pharma
License valid from 2017-06-02